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It is difficult to determine the cause of high fever in patients with advanced cancer, because these 
patients tend to have both neoplastic fever and bacterial infections with elevated white blood cell 
number and C-reactive protein level. Procalcitonin has been reported to be a valuable marker for 
prediction of bacterial infections in a wide range of clinical areas. However, there have been no 
studies regarding the usefulness of procalcitonin for differentiation between febrile episodes 
caused by bacterial infections and neoplastic fever in patients with advanced urological cancer. In 
the present study, to investigate the efficacy of procalcitonin for differentiation of bacterial 
infections, 37 febrile episodes were retrospectively analyzed. Although there were no differences 
in white blood cell number, C-reactive protein level, or body temperature between bacterial 
infections and non-bacterial infections, procalcitonin level was significantly higher in the former 
than the latter. Our findings show that measurement of procalcitonin may be valuable to 
determine the cause of febrile episodes in patients with advanced urological cancer and can help 










Patients with advanced cancer, which is associated with a huge volume of primary tumor or 
disseminated metastases, are susceptible to bacterial infections (BI) due to their poor systemic 
condition, and such BI usually cause high fever exceeding 38.0°C. Although most BI may be 
diagnosed quickly and easily because physical findings, blood tests, and radiological 
examinations can detect the focus of BI, some patients show no evidence of infection other than 
high fever and may only show high white blood cell (WBC) counts and C-reactive protein (CRP) 
levels. On the other hand, non-BI (NBI), such as neoplastic fever (NF), can also cause high fever 
and result in high WBC counts and CRP levels similar to BI. The possibility of NF increases as the 
tumor volume or number of metastases increases. Therefore, it is sometimes very difficult to 
determine the cause of high fever in patients with advanced cancer, especially when there is no 
association with febrile neutropenia. When BI is diagnosed immediately during febrile episodes, 
antibiotics will be administered appropriately. However, if the time of diagnosis is delayed, the 
possibility of inappropriate use of antibiotics for NBI will increase. In such cases, the patients’ 
relief from distress over high fever will also be delayed, and there is likely to be vast economic loss 
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due to the misuse of antibiotics. Procalcitonin (PCT) has been reported as a valuable serum 
marker for prediction of BI in a wide range of clinical areas. However, there have been no previous 
reports of the clinical usefulness of PCT for differentiation between febrile episodes caused by BI 
and NBI, mainly NF, in patients with advanced urological cancer. In the present study, we 
investigated the usefulness of PCT in patients with advanced urological cancer and our results 







All studies were performed retrospectively in Kanazawa University using charts of patients who 
were hospitalized in the Department of Urology from May 2009 to August 2010. Febrile episodes 
> 38.0°C in patients with advanced urological cancer were analyzed. The records of blood tests, 
including WBC, CRP, and PCT immediately after the onset of fever, were acquired for each febrile 
episode. Advanced urological cancer was defined as a large primary tumor (long diameter > 5 
cm) or the presence of metastasis. 
 
Definition of BI 
BI was defined according to the following criteria: positive blood culture, symptoms and obvious 
findings of BI on physical examination, and rapid recovery of fever after antibiotic administration. 
Radiological findings and results of urine and sputum culture were also taken into account for 
diagnosis. Febrile episodes that did not meet the criteria of BI were defined as NBI, and if no 





Statistical analyses were performed using commercially available software (Prism). Comparisons 
between two groups were performed by unpaired two-sided t test and chi-square test for trends. 
Comparisons among multiple groups were performed by chi-square test and one-way ANOVA. In 






Of 28 patients enrolled in the present study, 37 febrile episodes could be analyzed. In the overall 
patient population, the median age was 71 years (range, 14 – 84) and the numbers of cases of 
prostate cancer, urothelial carcinoma, renal cell carcinoma, germ cell tumor, and other type of 
malignant tumor were 11, 12, 6, 6, and 2, respectively. Nineteen had already undergone primary 
tumor resection and had metastatic lesions, and 18 still had the primary tumor. The median 
maximum axillary body temperature (BT), median WBC, and CRP were 38.5°C (range, 38.0°C – 
40.7), 7.77×103/μl (range, 2.04 – 31.07), and 10.3 mg/dl (range, 0.4 – 33.3), respectively. PCT 
were divided into 4 categories from – (< 0.5 ng/ml) to +++ (10.0 ng/ml), and the numbers of –, +, 
++, and +++ were 20, 8, 3, and 6, respectively (Table 1). 
 
Causes of febrile episodes 
Seventeen of 37 febrile episodes were regarded as BI, and the remaining 20 febrile episodes 
were regarded as NBI. Single blood culture was done in each of 29 febrile episodes and 4 were 
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positive. Of 17 BI, 6 were diagnosed as acute pyelonephritis, 3 were diagnosed as pneumonia, 
and the remaining 8 could not be diagnosed as a specific focal infection. Of 20 NBI, 3 were 
caused by reaction to injection of anti-tumor drugs, and 1 was caused by rheumatoid arthritis, 
accordingly, 16 were diagnosed as NF. 
 
Differences in background factors between BI and NBI 
First, the differences in WBC, CRP, and BT between BI and NBI were compared because these 
factors are generally regarded as signs that can reflect the severity of BI. As shown in Fig. 1, 
although there were no significant differences in WBC, CRP, or BT between BI and NBI, there 
was a significant difference between age in BI and NBI (P = 0.0048). Next, to determine whether 
the type of primary cancer has any relation to the cause of febrile episode, 4 primary cancer sites 
were compared. The results indicated significant differences between these primary cancer sites 
(Fig. 2 upper, P = 0.0005). However, there were also significant differences in age among these 4 
groups (Fig. 2 lower, P < 0.0001). Finally, the difference in PCT between BI and NBI was 
analyzed. Negative PCT was found 15 of 20 NBI and 5 of 17 BI. The results indicated that BI had 
significantly higher PCT compared with NBI (Fig. 3, upper, P = 0.0024). There were no 
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PCT is produced by thyroid C-cells and is detected in blood when severe inflammation occurs. 
Normally, the PCT level in serum is below the limits of detection because all PCT is converted into 
calcitonin. 1, 2 Therefore, PCT has been suggested to be a reliable marker for the severity of 
sepsis or bacteremia. 3, 4 In the adult hemato-oncological field, the role of PCT has been reported 
in studies. 5-7 The largest study assessed the PCT of 236 febrile episodes in 166 
hemato-oncological patients treated with aggressive chemotherapy, and showed that PCT 
increased in infections, but not in fever of unknown origin. 8 With regard to solid tumors, the role of 
PCT in febrile neutropenic patients has also been studied and it was reported that PCT was 
valuable as a diagnostic and prognostic tool in patients with febrile neutropenia. 1, 7, 9 There have 
been only 2 previous reports focusing not on febrile neutropenia in patients with solid tumor, but 
on febrile episodes without neutropenia. One study did not show the usefulness of PCT to 
discriminate between infections and other causes of febrile episodes. 10 Another study concluded 
that PCT was a good indicator of bacteremia. 11 However, these studies included few cases of 
urological malignancy as well as other studies focusing on the role of PCT in patients with 
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malignancy. Our results showed that age may contribute to an increase in the possibility of 
infection during febrile episodes in patients with advanced urological cancer. Our analysis 
suggested that cancer type also affects the increase in possibility of infection. However, age may 
be a confounding factor for this result (Fig. 2). On the other hand, PCT could predict infection 
although CRP and WBC could not predict infection in patients with advanced urological cancer. 
Although there were false positive and negative episodes in this study, 12 this result indicated that 
PCT is useful to discriminate between BI and NBI, mainly NF. This study had some limitations. It 
was a retrospective study with small sample size. This may have prevented determination of the 
precise statistical significance of differences between groups with bias.  Definition of BI might be 
incomplete because the single blood culture lacked in power to detect bacteremia. Larger 
prospective studies with proper definition of BI are needed to confirm our findings. In conclusion, 
this is the first study to show the usefulness of PCT in patients with advanced urological cancer, 
and PCT may be a rapid and affordable marker for differentiation between BI and NF in such 
patients. 
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Fig. 1 – Comparison of WBC, CRP, BT, and age between NBI (n = 20) and BI (n = 17). Unpaired 
two-sided t test was used. Bars, Means ± SEM. 
 
Fig. 2 – (Upper panel) The percentages of NBI and BI in 4 types of urological cancer. Chi-square 
test was used. (Lower panel) The distributions of age in 4 types of urological cancer. One-way 
ANOVA was used. Bars, Means ± SEM. PCa = prostate cancer, UC = urothelial carcinoma, RCC 
= renal cell carcinoma, GCT = germ cell tumor, Oth = other neoplasms. 
 
Fig. 3 – (Upper panel) The percentages of each PCT level in NBI and BI. Chi-square test for 
trends was used. (Lower panel) The distributions of age in each PCT level. One-way ANOVA was 




Patient characteristics (37 episodes in 28 patients) 
Age   71* (14 – 84) 
Gender Male  31 
 Female  6 
PS 0  2 
 1  11 
 2  4 
 3  4 
 4  16 
Cancer type PCa  11 
 UC  12 
  Bladder 8 
  Ureter 2 
  Renal pelvis 2 
 RCC  6 
 GCT  6 
 Other  2 
Primary tumor size (cm)**  8.6* (5.0 – 17.6) 
 resected  19 
BT (°C)   38.5* (38.0 – 40.7) 
WBC (×103/μl)   7.77* (2.04 – 31.07) 
CRP (mg/dl)   10.3* (0.4 – 33.3) 
PCT (ng/ml) - (< 0.5) 20 
 + (0.5 – 2.0) 8 
 ++ (2.0 – 10.0) 3 
  +++ (> 10.0) 6 
PS = performance status, PCa = prostate cancer, UC = urothelial carcinoma, 
RCC = renal cell carcinoma, GCT = germ cell tumor, BT = body temperature, 
WBC = white blood cell, CRP = c-reactive protein, PCT = procalcitonin. * 
median, ** not resected 
 
 



